Fate Therapeutics Inc (NAS:FATE)
$ 3.76 0.1 (2.73%) Market Cap: 428.01 Mil Enterprise Value: 135.15 Mil PE Ratio: 0 PB Ratio: 1.01 GF Score: 58/100

Fate Therapeutics Inc at Cowen IO Next Summit (Virtual) Transcript

Nov 11, 2022 / 07:10PM GMT
Release Date Price: $22.96 (+9.49%)
Tyler Van Buren
Cowen Inc. - Analyst

Great. Good afternoon, everyone. My name is Tyler Van Buren, senior biotech analyst at Cowen. Thank you again for joining us for Cowen's 6th Annual IO Next Summit. For this next session, I'm going to be moderating a fireside chat with Fate Therapeutics, and it's my pleasure to introduce Ed Dulac, Fate's Chief Financial Officer. Ed, it's a privilege to have you here. Thank you very much for joining us.

Ed Dulac
Fate Therapeutics, Inc. - CFO

Pleasure, Tyler. Thanks for having us.

Questions & Answers

Tyler Van Buren
Cowen Inc. - Analyst

(Conference Instructions) Now we'll go ahead and get into it. So Ed, I figured we'd start with SITC then move to ASH and then the Q1 R&D analyst event in order. So maybe starting with SITC and the solid tumor franchise, at a high level, why is Fate pursuing the combination of its iNKs with standard of care antibodies in solid tumors?

Ed Dulac
Fate Therapeutics, Inc. - CFO

Yes. So I mean,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot